Jaguar Health outlines dual NDA filing targets for late 2026 as clinical catalysts converge [Seeking Alpha]
Jaguar Health, Inc. (JAGX)
US:NASDAQ Investor Relations:
jaguarhealth.gcs-web.com/investor-overview
Company Research
Source: Seeking Alpha
Lisa Conte, Founder, CEO, President & Director, highlighted that combined net third quarter 2025 revenue of approximately $3.1 million for prescription and nonprescription products, including license revenue, increased approximately 4% versus net Q2 2025. Conte emphasized, "2025 continues to be the year Quick Insights Management states that late-stage milestones are expected to be transformative for stakeholders, potentially enhancing company value and offering significant catalysts for shareholders if achieved. Q3 2025 revenue grew slightly quarter-over-quarter to $3.1 million; Mytesi prescription growth slowed to 0.9% from 6.5% in the previous quarter and declined year-over-year. Loss from operations and net loss narrowed compared to Q3 2024. Jaguar Health depends on closing business development deals for non-dilutive funding and faces ambitious regulatory timelines contingent on continued clinical success and partnership agreements for late-stage assets. More Trending Ne
Show less
Read more
Impact Snapshot
Event Time:
JAGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAGX alerts
High impacting Jaguar Health, Inc. news events
Weekly update
A roundup of the hottest topics
JAGX
News
- Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue [Yahoo! Finance]Yahoo! Finance
- Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Jaguar Health GAAP EPS of -$6.28, revenue of $3.08M [Seeking Alpha]Seeking Alpha
- Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Scrubbed to Host Virtual Event on the Rise of Fractional Leadership, Finance and InnovationPR Web
JAGX
Sec Filings
- 11/26/25 - Form EFFECT
- 11/25/25 - Form 424B3
- 11/24/25 - Form D
- JAGX's page on the SEC website